Origins and effects of extracellular alpha-synuclein: implications in Parkinson's disease
- PMID: 18157654
- DOI: 10.1007/s12031-007-0012-9
Origins and effects of extracellular alpha-synuclein: implications in Parkinson's disease
Abstract
Misfolding and abnormal aggregation of the neuronal protein alpha-synuclein has been implicated in the pathogenesis of Parkinson's disease and related neurological disorders, such as dementia with Lewy bodies. alpha-synuclein is a conventional cytosolic protein and is thought to exert its pathogenic function exclusively in the neuronal cytoplasm in a cell-autonomous manner. However, the current model is being challenged by a series of new observations that demonstrate the presence of alpha-synuclein and its aggregated forms in the extracellular fluid both in vivo and in vitro. Extracellular alpha-synuclein appears to be delivered by unconventional exocytosis of intravesicular alpha-synuclein, although the exact mechanism has not been characterized. Compared to the cytosolic alpha-synuclein, intravesicular alpha-synuclein is prone to aggregation and the potential source of extracellular aggregates. A number of tissue culture studies suggest that exposure to extracellular alpha-synuclein aggregates induces microglial activation, release of pro-inflammatory cytokines from astrocytes, and neurotoxicity. Thus, exocytosis of alpha-synuclein may be an important mechanism for amplifying and spreading degenerative changes from a small group of cells to its surrounding tissues, and it potentially provides therapeutic targets for halting the progression of the disease.
Similar articles
-
Clearance and deposition of extracellular alpha-synuclein aggregates in microglia.Biochem Biophys Res Commun. 2008 Aug 1;372(3):423-8. doi: 10.1016/j.bbrc.2008.05.045. Epub 2008 May 19. Biochem Biophys Res Commun. 2008. PMID: 18492487
-
Immunotherapy in Parkinson's Disease: Micromanaging Alpha-Synuclein Aggregation.J Parkinsons Dis. 2015;5(3):413-24. doi: 10.3233/JPD-150630. J Parkinsons Dis. 2015. PMID: 26406122 Free PMC article. Review.
-
Microglial exosomes facilitate α-synuclein transmission in Parkinson's disease.Brain. 2020 May 1;143(5):1476-1497. doi: 10.1093/brain/awaa090. Brain. 2020. PMID: 32355963 Free PMC article.
-
Potential Modes of Intercellular α-Synuclein Transmission.Int J Mol Sci. 2017 Feb 22;18(2):469. doi: 10.3390/ijms18020469. Int J Mol Sci. 2017. PMID: 28241427 Free PMC article. Review.
-
Extracellular α--synuclein-a novel and crucial factor in Lewy body diseases.Nat Rev Neurol. 2014 Feb;10(2):92-8. doi: 10.1038/nrneurol.2013.275. Epub 2014 Jan 28. Nat Rev Neurol. 2014. PMID: 24468877 Review.
Cited by
-
Trans-synaptic and retrograde axonal spread of Lewy pathology following pre-formed fibril injection in an in vivo A53T alpha-synuclein mouse model of synucleinopathy.Acta Neuropathol Commun. 2020 Aug 28;8(1):150. doi: 10.1186/s40478-020-01026-0. Acta Neuropathol Commun. 2020. PMID: 32859276 Free PMC article.
-
α-Synuclein oligomers oppose long-term potentiation and impair memory through a calcineurin-dependent mechanism: relevance to human synucleopathic diseases.J Neurochem. 2012 Feb;120(3):440-52. doi: 10.1111/j.1471-4159.2011.07576.x. Epub 2011 Nov 28. J Neurochem. 2012. PMID: 22060133 Free PMC article.
-
Neuroproteomics as a promising tool in Parkinson's disease research.J Neural Transm (Vienna). 2008 Oct;115(10):1413-30. doi: 10.1007/s00702-008-0070-3. Epub 2008 Jun 4. J Neural Transm (Vienna). 2008. PMID: 18523721 Free PMC article. Review.
-
Inflammasomes as therapeutic targets in human diseases.Signal Transduct Target Ther. 2021 Jul 2;6(1):247. doi: 10.1038/s41392-021-00650-z. Signal Transduct Target Ther. 2021. PMID: 34210954 Free PMC article. Review.
-
Focus on the Role of NLRP3 Inflammasome in Diseases.Int J Mol Sci. 2020 Jun 13;21(12):4223. doi: 10.3390/ijms21124223. Int J Mol Sci. 2020. PMID: 32545788 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical